152 related articles for article (PubMed ID: 12781328)
21. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.
Li L; Huang YH; Li Y; Wang FQ; Shang BY; Zhen YS
World J Gastroenterol; 2005 Aug; 11(29):4478-83. PubMed ID: 16052675
[TBL] [Abstract][Full Text] [Related]
22. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
23. Apoptotic Melanoma B16-F1 Cells Induced by Lidamycin Could Initiate the Antitumor Immune Response in BABL/c Mice.
Yang JL; Qin Y; Li L; Cao CY; Wang Q; Li Q; Lv YF; Wang Y
Oncol Res; 2016 Jan; 23(1-2):79-86. PubMed ID: 26802654
[TBL] [Abstract][Full Text] [Related]
24. Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner.
Prokop A; Wrasidlo W; Lode H; Herold R; Lang F; Henze G; Dörken B; Wieder T; Daniel PT
Oncogene; 2003 Dec; 22(57):9107-20. PubMed ID: 14647446
[TBL] [Abstract][Full Text] [Related]
25. Lidamycin induces marked G2 cell cycle arrest in human colon carcinoma HT-29 cells through activation of p38 MAPK pathway.
Liu X; Bian C; Ren K; Jin H; Li B; Shao RG
Oncol Rep; 2007 Mar; 17(3):597-603. PubMed ID: 17273739
[TBL] [Abstract][Full Text] [Related]
26. Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice.
Zhen YZ; Lin YJ; Li Y; Zhen YS
Acta Pharmacol Sin; 2009 Jul; 30(7):1025-32. PubMed ID: 19575006
[TBL] [Abstract][Full Text] [Related]
27. Induction of apoptosis by enediyne antitumor antibiotic C1027 in HL-60 human promyelocytic leukemia cells.
Jiang B; Li DD; Zhen YS
Biochem Biophys Res Commun; 1995 Mar; 208(1):238-44. PubMed ID: 7887935
[TBL] [Abstract][Full Text] [Related]
28. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
29. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS
Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
[TBL] [Abstract][Full Text] [Related]
30. Amplification of C1027-induced DNA cleavage and apoptosis by a quinacrine-netropsin hybrid molecule in tumor cell lines.
Iwamoto T; Hiraku Y; Kojima M; Kawanishi S
Arch Biochem Biophys; 2005 Feb; 434(2):232-40. PubMed ID: 15639222
[TBL] [Abstract][Full Text] [Related]
31. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells.
Sha MQ; Zhao XL; Li L; Li LH; Li Y; Dong TG; Niu WX; Jia LJ; Shao RG; Zhen YS; Wang Z
Cell Death Dis; 2016 Nov; 7(11):e2486. PubMed ID: 27882937
[TBL] [Abstract][Full Text] [Related]
32. [The synergistic effect of lidamycin and rituximab on human B cell lymphoma].
Sun YR; Zhang SH; Shao RG; He HW
Yao Xue Xue Bao; 2014 Feb; 49(2):198-203. PubMed ID: 24761609
[TBL] [Abstract][Full Text] [Related]
33. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11].
Wang FQ; Shang BY; Zhen YS
Yao Xue Xue Bao; 2003 Jul; 38(7):515-9. PubMed ID: 14515796
[TBL] [Abstract][Full Text] [Related]
34. Antitumor efficacy of lidamycin against human multiple myeloma RPMI 8226 cells and the xenograft in nonobese diabetic/severe combined immunodeficiency mice.
Zhen Y; Shang B; Liu X; Lin Y; Zhen Y
J Cancer Res Ther; 2016; 12(1):182-7. PubMed ID: 27072234
[TBL] [Abstract][Full Text] [Related]
35. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
[TBL] [Abstract][Full Text] [Related]
36. [The role of caspase-3 in rapamycin-induced apoptosis of hepatocellular carcinoma BEL-7402 cells].
Zhang JF; Lu MQ; Cai CJ; Yang Y; Li H; Yi HM; Chen GH
Ai Zheng; 2006 Dec; 25(12):1508-11. PubMed ID: 17166376
[TBL] [Abstract][Full Text] [Related]
37. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis.
Yang XH; Sladek TL; Liu X; Butler BR; Froelich CJ; Thor AD
Cancer Res; 2001 Jan; 61(1):348-54. PubMed ID: 11196185
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers].
Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH
Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase.
Fengqiang W; Boyang S; Yongsu Z
Sci China C Life Sci; 2004 Feb; 47(1):66-73. PubMed ID: 15382678
[TBL] [Abstract][Full Text] [Related]
40. Lidamycin inhibits the cancer cell PKC activity induced by basic fibroblast growth factor.
Zhen HY; Huang YH; Zhen YS
Yao Xue Xue Bao; 2005 Dec; 40(12):1110-5. PubMed ID: 16496675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
